Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Antonin Dréan, Lauriane Goldwirt, Maïté Verreault, Michael Canney, Charlotte Schmitt, Jeremy Guehennec, Jean-Yves Delattre, Alexandre Carpentier & Ahmed Idbaih. (2016) Blood-brain barrier, cytotoxic chemotherapies and glioblastoma. Expert Review of Neurotherapeutics 16:11, pages 1285-1300.
Read now
Read now
Raffaele Addeo, Silvia Zappavigna, Amalia Luce, Sergio Facchini & Michele Caraglia. (2013) Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC. Expert Opinion on Drug Safety 12:5, pages 729-740.
Read now
Read now
Gaëlle Quéreux & Brigitte Dréno. (2011) Fotemustine for the treatment of melanoma. Expert Opinion on Pharmacotherapy 12:18, pages 2891-2904.
Read now
Read now
M. Ozkan, M. Altinbas, O. Er, B. Kaplan, H.S. Coskun, E. Karahacioglu, A. Menku, Y. Cihan, O. Kontas & H Akdemir. (2004) Post-Operative Sequential Chemo-Radiotherapy in High-Grade Cerebral Gliomas with Fotemustine. Journal of Chemotherapy 16:3, pages 298-302.
Read now
Read now
Marko B Lens & Tim G Eisen. (2003) Systemic chemotherapy in the treatment of malignant melanoma. Expert Opinion on Pharmacotherapy 4:12, pages 2205-2211.
Read now
Read now
Articles from other publishers (45)
Raffaele Addeo, Giuseppe Lamberti, Giorgia Simonetti, Patrizia Iodice, Alfredo Marinelli, Liliana Montella, Salvatore Cappabianca, Paola Gaviani, Michele Caraglia, Salvatore Del Prete & Antonio Silvani. (2019) Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study. CNS Oncology 8:2, pages CNS32.
Crossref
Crossref
Ali Mohammadpour, Maryam Derakhshan, Hassan Darabi, Pegah Hedayat & Mohammad Momeni. (2018) Melanoma: Where we are and where we go. Journal of Cellular Physiology 234:4, pages 3307-3320.
Crossref
Crossref
Alfredo Marinelli, Giuseppe Lamberti, Luigi Cerbone, Nadia Cordua, Carlo Buonerba, Gianfranco Peluso, Giuseppe Di Lorenzo & Sabino De Placido. (2018) High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients. Medicine 97:27, pages e11254.
Crossref
Crossref
Anfernee Kai-Wing Tse, Ying-Jie Chen, Xiu-Qiong Fu, Tao Su, Ting Li, Hui Guo, Pei-Li Zhu, Hiu-Yee Kwan, Brian Chi-Yan Cheng, Hui-Hui Cao, Sally Kin-Wah Lee, Wang-Fun Fong & Zhi-Ling Yu. (2017) Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKKβ inhibition. Redox Biology 11, pages 562-576.
Crossref
Crossref
Lijiao Zhao, Lili Li, Jie Xu & Rugang Zhong. (2014) Comparative investigation of the DNA inter-strand crosslinks induced by ACNU, BCNU, CCNU and FTMS using high-performance liquid chromatography?electrospray ionization tandem mass spectrometry. International Journal of Mass Spectrometry 368, pages 30-36.
Crossref
Crossref
Darshil J. Shah & Roxana S. Dronca. (2014) Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma. Mayo Clinic Proceedings 89:4, pages 504-519.
Crossref
Crossref
. 2014. The Melanocytic Proliferations. The Melanocytic Proliferations
488
509
.
V. Vaccaro, A. Fabi, A. Vidiri, D. Giannarelli, G. Metro, S. Telera, S. Vari, F. Piludu, M. A. Carosi, V. Villani, F. Cognetti, A. Pompili, L. Marucci, C. M. Carapella & A. Pace. (2014) Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas. BioMed Research International 2014, pages 1-7.
Crossref
Crossref
Antonio Daponte, Simona Signoriello, Luigi Maiorino, Bruno Massidda, Ester Simeone, Antonio Maria Grimaldi, Corrado Caracò, Giuseppe Palmieri, Antonio Cossu, Gerardo Botti, Antonella Petrillo, Secondo Lastoria, Ernesta Cavalcanti, Pasquale Aprea, Nicola Mozzillo, Ciro Gallo, Giuseppe Comella & Paolo Antonio Ascierto. (2013) Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma. Journal of Translational Medicine 11:1.
Crossref
Crossref
Patrick Beauchesne. (2012) Fotemustine: A Third-Generation Nitrosourea for the Treatment of Recurrent Malignant Gliomas. Cancers 4:1, pages 77-87.
Crossref
Crossref
Hedwig Stanisz, Thomas Vogt & Knuth Rass. 2012. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma
247
263
.
Patrick D. Beauchesne. 2011. Tumors of the Central Nervous System, Volume 1. Tumors of the Central Nervous System, Volume 1
341
347
.
Jean-François Morère, Françoise Mornex & Denis SoulièresR. Mouawad, D. Khayat & J.-P. Spano. 2011. Thérapeutique du cancer. Thérapeutique du cancer
673
683
.
Azadeh Orouji, Sergij Goerdt & Jochen Utikal. (2010) Systemic Therapy of Non-Resectable Metastatic Melanoma. Cancers 2:2, pages 955-969.
Crossref
Crossref
Kyaw Minn Hsan, Chun-Chieh Chen & Lie-Fen Shyur. (2010) Current Research and Development of Chemotherapeutic Agents for Melanoma. Cancers 2:2, pages 397-419.
Crossref
Crossref
Roger Mouawad, Marie Sebert, Judith Michels, Joel Bloch, Jean-Philippe Spano & David Khayat. (2010) Treatment for metastatic malignant melanoma: Old drugs and new strategies. Critical Reviews in Oncology/Hematology 74:1, pages 27-39.
Crossref
Crossref
Beatriz González Astorga, Berta Jiménez Rubiano, Juan Ramón Delgado Pérez, Javier Valdivia Bautista, Carmen Sánchez Toro, Encarnación González Flores, Raquel Luque Caro & Victoria Castellón Rubio. (2009) Biochemotherapy in the treatment of metastatic melanoma in selected patients. Clinical and Translational Oncology 11:6, pages 382-386.
Crossref
Crossref
Gloria M Calaf & Debasish Roy. (2007) Gene and Protein Expressions Induced by 17β-estradiol and Parathion in Cultured Breast Epithelial Cells. Molecular Medicine 13:5-6, pages 255-265.
Crossref
Crossref
X. Durando, E. Thivat, H. Roché, J.O. Bay, J-J. Lemaire, P. Verrelle, M-A. Lentz, J. Chazal, H. Curé & P. Chollet. (2006) Cystemustine in recurrent high grade glioma. Journal of Neuro-Oncology 79:1, pages 33-37.
Crossref
Crossref
Annett Hölsken, Ilker Y. Eyüpoglu, Mike Lueders, Christian Tränkle, Detlef Dieckmann, Rolf Buslei, Eric Hahnen, Ingmar Blümcke & Florian A. Siebzehnrübl. (2006) Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases. Acta Neuropathologica 112:2, pages 205-215.
Crossref
Crossref
Athena Christopoulou, Spyros Retsas, Derek Kingsley, Ian Paddick & Christer Lindquist. (2006) Integration of gamma knife surgery in the management of cerebral metastases from melanoma. Melanoma Research 16:1, pages 51-57.
Crossref
Crossref
Peter Mohr. 2006. Management des Melanoms. Management des Melanoms
349
362
.
Lee D. Cranmer, Katrina T. Trevor, Surekha Bandlamuri & Evan M. Hersh. (2005) Rodent models of brain metastasis in melanoma. Melanoma Research 15:5, pages 325-356.
Crossref
Crossref
Sanjiv S. Agarwala. (2005) In Reply:. Journal of Clinical Oncology 23:13, pages 3155-3156.
Crossref
Crossref
Sewa S. Legha. (2005) Treatment of Brain Metastases From Melanoma. Journal of Clinical Oncology 23:13, pages 3155-3155.
Crossref
Crossref
D. Bafaloukos & H. Gogas. (2004) The treatment of brain metastases in melanoma patients. Cancer Treatment Reviews 30:6, pages 515-520.
Crossref
Crossref
Dimitros Bafaloukos, Dimosthenis Tsoutsos, Georges Fountzilas, Helen Linardou, Christos Christodoulou, Haralambos P. Kalofonos, Erangelos Briassoulis, Petros Panagiotou, Helen Hatzichristou & Helen Gogas. (2004) The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Research 14:4, pages 289-294.
Crossref
Crossref
Ahmad A Tarhini & Sanjiv S Agarwala. (2004) Management of brain metastases in patients with melanoma. Current Opinion in Oncology 16:2, pages 161-166.
Crossref
Crossref
Sigmund H. Hsu & W. K. Alfred Yung. 2004. Intracranial Metastases. Intracranial Metastases
183
198
.
Gilles Vassal, Jean-Louis Merlin, Marie-José Terrier-Lacombe, Jacques Grill, Fabrice Parker, Christian Sainte-Rose, Geneviève Aubert, Jackie Morizet, Nicolas Sévenet, Marie-Gwenaëlle Poullain, Catherine Lucas & Chantal Kalifa. (2003) In vivo antitumor activity of S16020, a topoisomerase II inhibitor, and doxorubicin against human brain tumor xenografts. Cancer Chemotherapy and Pharmacology 51:5, pages 385-394.
Crossref
Crossref
A. Schmittel, T. Proebstle, R. Engenhart-Cabillic, C. Scheibenbogen, A.-M. Geueke, E. Thiel & U. Keilholz. (2003) Brain metastases following interleukin-2 plus interferon-alpha-2a therapy. European Journal of Cancer 39:4, pages 476-480.
Crossref
Crossref
F Mornex, L Thomas, P Mohr, A Hauschild, M M Delaunay, T Lesimple, W Tilgen, B N Bui, B Guillot, J Ulrich, S Bourdin, M Mousseau, D Cupissol, M E Bonneterre, C de Gislain, R J Bensadoun & M Clavel. (2003) A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Research 13:1, pages 97-103.
Crossref
Crossref
F Mornex, L Thomas, P Mohr, A Hauschild, M.M Delaunay, T Lesimple, W Tilgen, B.B Nguyen, B Guillot, J Ulrich, S Bourdin, M Mousseau, D Cupissol, J Bonneterre, C de Gislain, J.R Bensadoun & M Clavel. (2003) Essai de phase III randomisé comparant la fotémustine seule ou associée à une irradiation encéphalique dans les métastases cérébrales de mélanome†. Cancer/Radiothérapie 7:1, pages 1-8.
Crossref
Crossref
James G. Douglas & Kim Margolin. (2002) The treatment of brain metastases from malignant melanoma. Seminars in Oncology 29:5, pages 518-524.
Crossref
Crossref
Fabrice Branle, Florence Lefranc, Isabelle Camby, Judith Jeuken, Anneke Geurts‐Moespot, Sandra Sprenger, Fred Sweep, Robert Kiss & Isabelle Salmon. (2002) Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 95:3, pages 641-655.
Crossref
Crossref
Markus Christmann, Matthias Pick, Hermann Lage, Dirk Schadendorf & Bernd Kaina. (2001) Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene mgmt. International Journal of Cancer 92:1, pages 123-129.
Crossref
Crossref
John M. Kirkwood, Michael T. Lotze & Joyce M. YaskoStanton L. Gerson. 2001. Current Cancer Therapeutics. Current Cancer Therapeutics
1
36
.
J. C. Becker, E. Kämpgen & E.-B. Bröcker. (2000) Classical chemotherapy for metastatic melanoma. Clinical and Experimental Dermatology 25:6, pages 503-508.
Crossref
Crossref
P. Terheyden, J. C. Becker, E. Kämpgen & E. -B. Bröcker. (2000) Sequential interferon-α2b, interleukin-2 and fotemustine for patients with metastatic melanoma. Melanoma Research 10:5, pages 475-482.
Crossref
Crossref
Richard B Roth & Leona D Samson. (2000) Gene transfer to suppress bone marrow alkylation sensitivity. Mutation Research/Reviews in Mutation Research 462:2-3, pages 107-120.
Crossref
Crossref
Jeanette M. Pitts & Mary E. Maloney. (2000) THERAPEUTIC ADVANCES IN MELANOMA. Dermatologic Clinics 18:1, pages 157-167.
Crossref
Crossref
T Dine, F Khalfi, B Gressier, M Luyckx, C Brunet, L Ballester, F Goudaliez, J Kablan, M Cazin & J.C Cazin. (1998) Stability study of fotemustine in PVC infusion bags and sets under various conditions using a stability-indicating high-performance liquid chromatographic assay. Journal of Pharmaceutical and Biomedical Analysis 18:3, pages 373-381.
Crossref
Crossref
Jean E. Sanders. (1997) BONE MARROW TRANSPLANTATION FOR PEDIATRIC MALIGNANCIES. Pediatric Clinics of North America 44:4, pages 1005-1020.
Crossref
Crossref
Matthew G. Ewend, Lisa A. Carey & Henry Brem. (1996) Treatment of melanoma metastases in the brain. Seminars in Surgical Oncology 12:6, pages 429-435.
Crossref
Crossref
Eric Raymond, Corinne Haon, Catherine Boaziz & Maylis Coste. (1996) Logistic regression model of fotemustine toxicity combining independent phase II studies. Cancer 78:9, pages 1980-1987.
Crossref
Crossref